Abstract
Levamisole, used in vitro at therapeutic concentrations, was found able to restore the defective Fc-receptor activity of cancer patient neutrophils. In addition, the drug prevented the inhibition of normal neutrophils Fc-receptor function by cancer patient sera. The neutrophil Fc-receptor function was also restored in six of seven cancer patients after in vivo administration of levamisole (2.5 mg/Kg/day for 3 days). Due to the central role played by the Fc-receptor function in host defence mechanisms, including phagocytosis as well as antibody dependent cellular cytotoxicity, the capacity of levamisole to restore defective neutrophil Fc-receptor function in cancer patients could contribute to the 'immunomodulating' effect of the drug.
| Original language | English |
|---|---|
| Pages (from-to) | 1668-1672 |
| Number of pages | 5 |
| Journal | Cancer |
| Volume | 55 |
| Issue number | 8 |
| Publication status | Published - 1985 |
ASJC Scopus subject areas
- Cancer Research
- Oncology